Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 19/20 | 0.72 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | PRKACA | P17612 | 2/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.48 |
| ▸ | AKT1 | P31749 | 2/20 | 0.48 |
| ▸ | AKT2 | P31751 | 2/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | PRKX | P51817 | 2/20 | 0.48 |
| ▸ | NEK4 | P51957 | 2/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.48 |
| ▸ | PRKG2 | Q13237 | 2/20 | 0.48 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.48 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.48 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.48 |
| ▸ | SGK2 | Q9HBY8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27723747 | 1.00 | ROCK2 (0.72) | ROCK2ROCK1MAPK1RPS6KA5MAP4K4 | |
| SCHEMBL4533393 | 0.84 | ROCK2 (1.00) | ROCK2ROCK1MAPK1RPS6KA5MAP4K4 | |
| SCHEMBL16227497 | 0.84 | ROCK2 (1.00) | ROCK2ROCK1MAPK1RPS6KA5MAP4K4 | |
| SCHEMBL4531729 | 0.84 | ROCK2 (1.00) | ROCK2ROCK1MAPK1RPS6KA5MAP4K4 | |
| SCHEMBL4526995 | 0.81 | ROCK2 (0.68) | ROCK2ROCK1MAPK1RPS6KA5MAP4K4 | |
| SCHEMBL27723721 | 0.81 | ROCK2 (0.68) | ROCK2ROCK1MAPK1RPS6KA5MAP4K4 | |
| SCHEMBL4522397 | 0.81 | ROCK2 (0.68) | ROCK2ROCK1MAPK1RPS6KA5MAP4K4 | |
| SCHEMBL27744405 | 0.79 | ROCK2 (0.73) | ROCK2ROCK1MAPK1RPS6KA5PRKACA | |
| SCHEMBL4512609 | 0.79 | ROCK2 (0.73) | ROCK2ROCK1MAPK1RPS6KA5PRKACA | |
| SCHEMBL4518116 | 0.76 | ROCK2 (0.62) | ROCK2ROCK1MAPK1RPS6KA5MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| CN-101253152-A | Amide derivatives as ROCK inhibitors | ASTELLAS PHARMA INC (JP) | 2008-08-27 | — | — | CN | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885MAPK1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.